FDA Clearance Tracker · P240042
Tendyne Transcatheter Mitral Valve System
Last checked: Nov 19, 2026Latest source record: May 23, 2025 (this decision)Source: openFDAMethods & limitations
Decided
May 23, 2025
Approved
Time to decision
177 days
Received Nov 27, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P240042
- Device name
- Tendyne Transcatheter Mitral Valve System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- St. Paul, MN
- Received
- Nov 27, 2024
- Decided
- May 23, 2025
- Decision
- Approved
- Supplements
- 4 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the Tendyne Transcatheter Mitral Valve System. This device is indicated for the treatment of symptomatic severe mitral valve dysfunction (moderate-to-severe or severe mitral regurgitation [MR], severe mitral stenosis [MS], or moderate MR with moderate or greater MS) associated with severe mitral annular calcification (MAC) in patients who are deemed unsuitable for mitral valve surgery or transcatheter edge-to-edge repair by a multidisciplinary heart team.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NPU. The earliest in FDA's data is P140031-S162, decided May 23, 2024.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.